3.58  -0.15 (-4.02%)		12-05 16:00
Open: 3.7 High: 3.78 Volume: 4,253,772		Pre. Close: 3.73 Low: 3.485 Market Cap: 538(M)

Short term
Mid term
Targets	6-month :	5.11	1-year :	5.97
Resists	First :	4.38	Second :	5.11
Pivot price	3.06
Supports	First :	3.27	Second :	2.59
MAs	MA(5) :	3.33	MA(20) :	3.1
	MA(100) :	3.2	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	76.6	D(3) :	66.9
RSI	RSI(14): 55.9
52-week	High :	6.32	Low :	2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ABSI ] has closed below upper band by 2.6%. Bollinger Bands are 8.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	3.78 - 3.81	3.81 - 3.83
Low:	3.44 - 3.46	3.46 - 3.48
Close:	3.55 - 3.58	3.58 - 3.62

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Fri, 05 Dec 2025
Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine? - simplywall.st

Fri, 05 Dec 2025
Absci (NASDAQ:ABSI) Stock Price Up 10.8% - Still a Buy? - MarketBeat

Fri, 05 Dec 2025
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - Eastern Progress

Thu, 04 Dec 2025
Absci Stock’s Financial Prospects: An In-Depth Analysis - StocksToTrade

Thu, 04 Dec 2025
Absci Corp. Strives for New Horizons Amid Financial Adjustments - timothysykes.com

Thu, 04 Dec 2025
Absci (ABSI): Assessing Valuation as AI‑Designed Hair Loss Drug Enters First Phase 1/2a Trial - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	150 (M)
Held by Insiders	1.3278e+008 (%)
Held by Institutions	9.2 (%)
Shares Short	31,060 (K)
Shares Short P.Month	0 (K)

EPS	-1.055e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-7 %
Return on Assets (ttm)	977.2 %
Return on Equity (ttm)	-30.7 %
Qtrly Rev. Growth	2.81e+006 %
Gross Profit (p.s.)	-36.7
Sales Per Share	-26.27
EBITDA (p.s.)	-3.31274e+007
Qtrly Earnings Growth	-1 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-81 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.14
Price to Cash Flow	5.42

Dividend	0
Forward Dividend	3.2e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.